Find clinical trials

This is an early-stage (Phase 1b) study to test the safety and tolerability of a study drug called OM336 in people with pemphigus that has not responded well to standard treatments. OM336 is administered subcutaneously in ascending dose cohorts. Eligible participants will receive four injections of the study drug over a month. After this period, all participants will continue on the study and be monitored for up to 48 weeks. What is involved? A screening period of up to 28 days to check eligibility, A 4-week treatment period where participants will receive the study drug, A follow-up period (with regular visits for health checks, blood tests and study assessments) of up to 48 weeks after the last dose of study drug.